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The human immunodeficiency virus (HIV) is 
thought to invade the central nervous system (CNS) 
early in the course of infection. Infected individuals 
may develop cognitive impairment of varying 
severity, ranging from mild deficits evident only on 
formal cognitive testing to severe HIV-associated dementia (HIV-D). 
This spectrum of disease is known collectively as HIV-associated 
neurocognitive disorders (HAND).[1]
HAND is highly prevalent: it is estimated that 30 - 60% of HIV-
positive individuals are affected.[2] The resulting cognitive impairment 
can interfere with social and occupational functioning, and affect 
adherence to antiretroviral therapy (ART).[3] With the success of 
ART and now much longer life expectancy for HIV-infected persons, 
treatment of HIV has shifted from palliation to chronic disease 
management. Functional outcomes and quality of life concerns, 
including cognitive ability, have become all the more important.[4]
The majority of the worldwide HIV burden lies in sub-Saharan 
Africa. Clade C is the predominant HIV-1 subtype in South Africa. [5] 
Only a few studies have been done in distinct clade C cohorts, and 
these suggest a high risk of HAND.[6,7]
Since the introduction of ART, the incidence of HIV-D has decreased 
in the developed world from approximately 16% of HIV-positive 
patients being affected to less than 5%.[8-10] ART typically produces 
a significant improvement in neurocognitive status within 6 months 
of treatment.[11] This does not, however, imply a complete recovery 
in all cases. In fact, incident cases of cognitive dysfunction can still 
arise while patients are on suppressive ART regimens. Prevalence rates 
of the milder forms of HAND may even have increased in the era of 
ART.[10,12,13] This is partly attributable to longer survival (with longer 
overall exposure to the neurological effects of HIV), and to increased 
awareness and diagnosis of HAND. However, it may also relate to 
incomplete control of the virus and its effects on the CNS, and possibly 
to neurotoxicity of the antiretrovirals themselves.[14]
One of the proposed reasons for the continually high incidence of 
HAND in the ART era relates to the difficulty posed by the blood-
brain barrier (BBB) for the passage of drugs into the CNS. Although 
previously investigated by many groups, a CNS penetration effectiveness 
(CPE) ranking system was formally proposed by Letendre et al.[15] in 
2008 and updated in 2010.[16] This system ranks different antiretroviral 
agents according to their ability to cross the BBB and achieve control 
of HIV replication in the CNS. Each antiretroviral agent was assigned 
a score according to its chemical properties, cerebrospinal fluid (CSF) 
plasma concentrations, and effectiveness in achieving CNS HIV 
control (1 = below average; 2 = average; 3 = above average; 4 = much 
above average). A regimen score can be calculated by adding the 
individual agent scores. A regimen with a total score of ≤7 is considered 
to have low penetration in the CNS, while a score of >7 is considered 
to be highly penetrant.[17] There is convincing evidence that this 
system correctly identifies regimens that will achieve control of HIV 
replication in the CNS, i.e. regimens with higher CPE have been shown 
to be associated with CSF viral load (VL) suppression.[15] However, 
studies looking at the correlation between cognitive outcomes and 
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higher CPE regimens have shown mixed results.[18-22] Tozzi et al.[18] 
and Letendre et al.[21] both found an association between higher CPE 
regimens and improved neuropsychological function, while Rourke et 
al.[19] and Ciccarelli et al.[20] found no association between CPE scores 
and cognitive outcomes. Marra et al.[22] found an association between 
higher CPE scores and poorer cognitive performance, which they 
suggested may relate to increased drug toxicity given the increased 
CNS penetration.
ART only became readily available in South Africa’s public sector 
in 2003 (as opposed to 1996 in the developed world), and access 
remains limited in some areas. Additionally, until very recently 
national guidelines allowed that the majority of patients be started on 
ART only when their CD4 count fell below 200 cells/µl.[23] This is in 
contrast to the 350 cells/µl advised by the World Health Organization 
(WHO),[24] and to which South African guidelines were amended in 
August 2011.[25] If a diagnosis of HIV-D is made, the patient can be 
classified as WHO disease stage IV, and will then be considered for 
ART regardless of CD4 count. However, no provision is currently 
made for the milder forms of HAND. The fact that the South African 
ART threshold was a CD4 count less than 200 cells/µl for so long 
could have resulted in a higher prevalence of HAND in our setting, 
given that more advanced immunosuppression has been related to an 
increased risk of HAND.[10]
In addition to the heavy burden of HIV disease, South Africa 
is a resource-poor setting. This equates to busy, often under-
resourced clinics, where there is minimal time for the lengthy patient 
consultations that may be necessary to detect the subtler forms of 
HAND. Furthermore, as a result of protocol-driven management in the 
public sector, we have limited scope for individualised ARV choices.
Of note is the change in the South African Antiretroviral Guidelines 
in April 2010.[23] This change was largely aimed at discontinuing the 
use of the agent stavudine, and replacing it with tenofovir. Although 
the new first-line regimen is better tolerated, it has a lower CPE 
ranking (7 or 8 previously, compared with 6 or 7 currently), which 
may be significant in terms of cognitive outcomes in HIV. Concerns 
had been raised that widespread use of a lower CPE regimen might 
increase the incidence of HAND at a population level.
Also of interest is that the first-line regimen for pregnant women, 
zidovudine, lamivudine and nevirapine, has a CPE ranking of 10. This 
regimen would then be continued after pregnancy unless unacceptable 
side-effects or treatment failure necessitated a change. These two main 
regimens currently in use in South Africa create an interesting split 
of HIV-positive patients using high- and low-ranking CPE regimens.
The recent change in the South African first-line ART regimen 
from a higher to a lower CPE regimen, as well as the existence of the 
group of HIV-positive patients on the pregnancy regimen, allowed 
examination of the difference in cognitive outcomes according to 
ART regimen CPE in an HIV-1 clade C-specific cohort.
Objective
To examine the effect of ART regimen CPE on cognitive function 
in clade C-infected HIV-positive people. We did this by comparing 
cognitive outcomes between the group receiving the pre-April 2010 
ART regimen and the pregnancy regimen (both higher CPE) and 
the post-April 2010 lower CPE ART regimen. We hypothesised 
that patients receiving the higher CPE regimens would have better 
cognitive outcomes after 1 year.
Methods
This study formed part of a collaborative research programme into 
HIV-associated neurocognitive disorders in the Western Cape Province 
of South Africa by the departments of Psychiatry, Neurology and 
Geriatric Medicine at Groote Schuur Hospital/University of Cape Town. 
The research project was approved by the Human Research Ethics 
Committee of the Faculty of Health Sciences at the University of Cape 
Town (REC 263/2007, amendment 19 May 2008, and REC 203/2008).
HIV-positive participants attending primary level ARV clinics for 
highly active antiretroviral therapy initiation were recruited from 
Nolungile Clinic in Site C, Khayelitsha, Woodstock Community 
Health Centre and Mitchells Plain Community Health Centre. HIV-
negative control participants, recruited from voluntary counselling 
and testing centres in the same areas, were included to assess the 
neuropsychological norms for the population.
Entry criteria included being between the ages of 18 and 35 
years and having completed 7 years of schooling. Participants with 
uncontrolled medical conditions, other psychiatric or neurological 
disorders, substance or alcohol abuse or previous moderate to severe 
head injury were excluded.
The participants were assessed initially (pre-ART) and followed 
up approximately a year later. A neuropsychological test battery was 
administered at both visits to derive two sets of global deficit scores 
(GDSs).[26,27]
HIV-negative, demographically similar, control participants 
(N=103) underwent testing with a full neuropsychological battery, 
encompassing several different domains of cognitive function. This 
created a set of ‘normal’ raw scores for each test, which allowed 
computation of the ‘normal’ mean and standard deviation for each 
test in the specific study population. Summary scores for each ability 
domain were calculated by adding the individual standard scores for 
each test covering that domain, and dividing by the number of such 
tests. The specific scores used for each domain were: non-dominant 
hand scores for the finger tapping test and grooved pegboard test 
(motor), Hopkins Verbal Learning Test recall and Brief Visuospatial 
Memory Test recall scores (learning), Mental Alternation Test and 
Wechsler Memory Scale III mental control scores (attention), Digit 
Symbol Coding, Trail Making Test A and Colour Trails I (processing 
speed), Colour Trails II, Stroop Colour Word, Wisconsin Card 
Sorting Test perseverative errors and Rey-Osterrieth Complex Figure 
copy scores (executive function), and animal and fruit/vegetable 
fluency scores (verbal). This ‘summary Z-score’ for each domain was 
then converted to a t-score, and t-scores were converted to deficit 
scores according to the schema proposed by Heaton et al.[26] The GDS 
was calculated by adding the deficit scores from each domain, and 
dividing by the total number of added scores.
Although the cut-point of ≥0.50 has been shown to have the best 
diagnostic accuracy in terms of impairment,[27] different cut-points 
could be used. By definition, a GDS of 0 implies normality, while 
larger numbers imply worsening neuropsychological impairment.
For the purpose of this study, the participants were grouped into 
three categories of neuropsychological impairment: normal (GDS 
<0.25), mild-moderate impairment (0.25≤GDS<0.75) and severe 
impairment (GDS ≥0.75). This approach was developed by Joska 
et al.,[28] and the three groups were shown to correlate moderately 
well with the HAND diagnoses as defined by Antinori et al.[1] of 
normal function, asymptomatic neurocognitive impairment/mild 
neurocognitive disorder (as these essentially have the same degree of 
neuropsychological impairment, but differ on functional status) and 
HIV-D. Using this approach instead of the defined HAND categories 
removes the need to undertake an assessment of activities of daily 
living and related functional impairment.
Details regarding ART (including regimen, duration and virological 
response) were collected at the follow-up visit. Participants were 
excluded if they had not been on one consistent ART regimen 
for at least 10 months, and if they were not virally suppressed on 
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their ART regimens. Those meeting the ART 
requirements had CPE scores assigned to their 
regimens. A small number of participants 
were found still to be ART-naïve a year later, 
and were used as unintended controls to 
examine the effect of exposure to ART.
Data were analysed using STATA 
(version 11). The level of statistical significance 
was set at p=0.05. Distributions of the variables 
were determined using the Shapiro-Wilk 
test, and then parametric or nonparametric 
methods used as appropriate. Analysis of 
variance (ANOVA) and the Wilcoxon rank-
sum and Pearson chi-square tests were used 
for the analyses. ANOVA tests were done to 
compare the baseline characteristics of the 
cognitive function groups. Pearson chi-square 
tests were used to compare the change in 
cognitive function category, firstly between 
the ART and no-ART groups, and secondly 
for the higher CPE versus lower CPE groups. 
Wilcoxon rank-sum tests were used to compare 
these changes as a continuous variable, using 
the actual GDS score change.
Results
We obtained complete data on 111 
participants, of whom 89 had been initiated 
on ART and 22 had not; 69 of the 89 met 
the ART requirements (listed above) to be 
included in the CPE analysis. Of these 69, 
31 were classified into the low-regimen CPE 
category, while 38 were in the high-regimen 
CPE category (Fig. 1).
All those initiated on ART had a CD4 
count below 350 cells/µl. For this reason 2 
of the ART-naïve participants were excluded 
from the analysis because their CD4 counts 
were above 350 cells/µl, making them not 
comparable to the ART group.
The baseline characteristics of the 
cognitive function groups showed no 
significant difference in terms of CD4 count 
and most demographic features, with the 
exception of level of education (p≤0.001). 
The groups that did and did not receive ART 
were similar in terms of baseline CD4 count 
(mean 162.32 v. 181.15 cells/µl), t-test (df 
86, t=-1.10, p=0.275) and GDS (median 0.27 
v. 0.33, Wilcoxon rank-sum test: Z=-0.154, 
p=0.878). Table 1 shows the breakdown of 
the cognitive function groups according to 
ART and CPE category.
To analyse the change in cognitive function 
with respect to ART status, we analysed 
how many of the participants maintained 
or improved cognition, and how many 
worsened. This was done by comparing the 
follow-up GDS with the baseline GDS.
Of the ART group, 56 (81.2%) maintained 
or improved cognitive function, while 13 
(18.8%) worsened. Of the non-ART group, 
11 (55.0%) maintained or improved cognitive 
function, while 9 (45.0%) deteriorated. There 
was a significant difference in cognitive 
response between the group that had received 
ART and the group that had not (Pearson’s 
chi-square test: χ2 (1, n=89)=5.70, p=0.017). 
More of those patients who had received 
ART than those who had not, maintained 
or improved cognitive function (Fig. 2). The 
actual GDS change was also examined as a 
continuous variable between the two groups 
(ART group -0.07, non-ART group 0). The 
ART group had a greater GDS improvement 
(Wilcoxon rank-sum test: Z=-2.09, p=0.036).
Of the high CPE group, 32 (84.2%) 
maintained or improved cognitive function, 
while 6 (15.8%) worsened. Of the low CPE 
group, 24 (77.4%) maintained or improved 
cognitive function, while 7 (22.6%) 
deteriorated (Fig. 3). There was no significant 
difference in cognitive response between the 
higher and lower CPE regimen groups at the 
1-year follow-up visit (Pearson’s chi-square 
test: χ2 (1, n=69)=0.51, p=0.473.) Similarly, 
the median GDS changes in the high CPE 
group (-0.13) and the low CPE group (0) 
were not significantly different (Wilcoxon 
rank-sum test: Z=0.99, p=0.320).
Discussion
To our knowledge, this is the first published 
study from South Africa reporting on 
neurocognitive outcomes in patients 
receiving low and high CPE scoring ART 
Table 1. Breakdown of cognitive function groups according to ART and CPE category
Baseline cognitive function group
n
ART category CPE category
ART Non-ART Low CP High CPE
Normal cognitive function, GDS <0.25 33 8 15 18
Mild-moderate impairment, 0.25≤GDS<0.75 21 9 10 11 
Severe impairment, GDS ≥0.75 15 3 6 9








111 total with HAART data:
89 on HAART (69 pure
regimens, ≥10 months)
22 not on HAART 
(20 with CD4 count ≤350)
CPE analysis
N=69
(≤7 n=31, >7 n=38)
• Neuropsychological test battery
• Medical assessment
• Neuropsychological test battery
• HAART information collection
  (duration, regimen, response to ARVs)
Approx. 1 year
6 excluded: 3 RPR-positive, 3 HAART
virological failure
• Demographically similar, HIV-negative, for
  neuropsychological norms
Controls:
Primary level ARV clinics, Cape Town
Inclusion and exclusion criteria:
•  Informed consent, 18 - 35 years, 
    reading and writing grade 7 level
•  No signicant co-morbidities, substance abuse
   or previous head injury
•  ARV-naive, being prepared for HAART
Fig. 1. Flow diagram of the study process (ARV = antiretroviral; HAART = highly active antiretroviral 
therapy; HIV = human immunodeficiency virus; RPR = rapid plasma reagin; CPE = central nervous 
system penetration effectiveness).
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regimens. We noted that ART was beneficial in preserving, and in 
some cases improving, cognitive function in patients with CD4 counts 
of ≤350  cells/µl. We found no association between the CPE of the 
ART regimen used and cognitive outcome after 1 year, i.e. cognitive 
outcomes did not differ between participants treated with the previous 
first-line regimen (CPE 7/8), the new first-line regimen (CPE 6/7) or 
the regimen initiated during pregnancy (CPE 10).
Although there is convincing evidence that the CPE system correctly 
identifies regimens that will achieve control of HIV replication in 
the CNS,[15,22] studies looking at the correlation between cognitive 
outcomes and higher CPE regimens have shown mixed results.
Tozzi et al.[18] and Letendre et al.[21] both found an association 
between higher CPE regimens and improved neuropsychological 
function. This finding was expected, given the improved CSF VL 
control. However, Rourke et al.[19] and Ciccarelli et al.[20] found no 
association between CPE scores and cognitive outcomes. In this regard 
it is important to remember that CSF VL is not necessarily equivalent 
to brain VL. Postmortem studies have shown higher levels of HIV in 
brain tissue than in the CSF of the same patients.[29]
Marra et al.[22] found an association between higher CPE scores 
and poorer cognitive performance, which they suggested may relate 
to increased drug toxicity given the increased CNS penetration. ART 
itself may have CNS neurotoxic properties, especially given the well-
described toxic effects on peripheral nerves. Neurochemical studies 
have shown that almost all antiretroviral agents induce some degree 
of neuronal dysfunction.[30,31] Clinical studies have also suggested 
potential ART neurotoxicity. For example, Robertson et al.[14] showed 
significant improvement in cognitive function in a cohort of patients 
taken off ART.
There are many possible reasons for the conflicting literature 
regarding cognitive changes on higher CPE regimens. These include 
differing study designs, differing methods of assessing and classifying 
neuropsychological function, and small sample sizes. Study numbers 
range from 31 (Letendre et al.[21]) to 255 (Rourke et al.[19]). Letendre 
et al.[21] also noted that neuropsychological improvement was greater 
in ART-naïve participants, possibly because participants on ART 
accumulated resistant mutations. Some of the above studies have 
been done using ART-naïve participants,[18,19] and others naïve and 
experienced participants.[20-22]
Not all studies measured both CSF VL response and cognitive 
outcomes. Tozzi et  al.[18] noted that the correlation between higher 
CPE score and neuropsychological improvement was exclusive to those 
who achieved CSF VL suppression. This suggests that VL suppression 
rather than ART regimen was the key factor. Higher CPE regimens do, 
however, usually achieve greater CSF VL suppression.
Our findings are consistent with international studies that also 
showed no association between ART regimen CPE and cognitive 
outcomes.[19,20] However, as the literature shows, further research is still 
required in this area.
Study limitations 
There was a relatively small number of participants for the CPE 
analysis, and a short follow-up. However, 1 year is not an unreasonable 
follow-up period, given that it has been shown that significant 
cognitive improvement is usually seen within 6  months of starting 
ART.[11] It could be argued that a selection bias exists in this study, 
in terms of excluding those participants not on suppressive ART 
regimens for ≥10 months. These participants may have had poorer 
cognitive function and therefore greater difficulty in accessing 
and adhering to ART. However, this study was primarily aimed 
at comparing different ART regimens, and these exclusions were 
therefore necessary. It was also unfortunate that CSF testing could not 
form part of this study. We did not have ethics approval to perform 
lumbar punctures, as the participants were well outpatients who did 
not require this test as part of their clinical management.
Our findings do, nevertheless, suggest that the new lower CPE-ranking 
first-line ART regimen may be as neuroprotective as the previous higher 
penetration regimen. We did not find an increased prevalence of HAND 
in the lower CPE regimen group at 1 year. We do not yet know whether 
these neuropsychological improvements will persist beyond a year, or 
what the impact will be on daily function. Ideally a larger study should be 
conducted, with both CSF and neuropsychological testing and a longer 
follow-up period of several years.
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